Eli Lilly is doubling down on neuroscience, announcing a $6.3 billion all-cash deal to acquire Centessa Pharmaceuticals and its late-stage narcolepsy drug candidate.

The move, unveiled March 31, 2026, gives Lilly a promising orexin agonist currently in Phase 3 trials—a potential game-changer for sleep disorders like narcolepsy and idiopathic hypersomnia. The deal is expected to close in the second half of 2026, pending regulatory approval.

Why This Matters

Sleep disorders remain a stubbornly underserved market. Narcolepsy alone affects roughly 1 in 2,000 people worldwide, yet treatment options are limited and often come with safety or efficacy tradeoffs. Centessa’s lead asset, an oral orexin agonist, is widely viewed as one of the most advanced and differentiated therapies in late-stage development.

For Lilly, the acquisition isn’t just about one drug. It’s a strategic play to diversify beyond its diabetes and oncology mainstays, and to capture a bigger slice of the neuroscience market—a sector where Big Pharma is suddenly spending big after years of caution.

The Numbers

• Acquisition price: $6.3 billion, all-cash (Fierce Biotech)
• Deal announced: March 31, 2026
• Lead asset: Centessa’s orexin agonist for narcolepsy (Phase 3)
• Expected close: H2 2026, subject to regulatory approval

Strategic Context

This isn’t Lilly’s first neuroscience splash. In the past two years, the company has ramped up investment in Alzheimer’s and migraine drugs, chasing high unmet needs and blockbuster potential. The Centessa deal signals Lilly’s intent to be a serious player in sleep medicine—a space where rivals like Jazz Pharmaceuticals and Takeda have long dominated.

Centessa’s orexin agonist stands out for its mechanism: targeting the brain’s orexin pathway, a central regulator of wakefulness. If approved, it could offer a new option for patients poorly served by stimulants or sodium oxybate-based therapies, which come with side effects and scheduling hassles.

“This acquisition positions Lilly at the forefront of innovation in sleep medicine,” said Daniel Skovronsky, Lilly’s chief scientific officer, in a statement. “We see significant potential for orexin agonists to address the needs of patients with narcolepsy and other sleep disorders.”

Market Implications

The narcolepsy drug market is projected to reach $4.5 billion globally by 2030, according to GlobalData. With Centessa’s asset potentially launching as early as 2027, Lilly could quickly capture share from incumbents—assuming the Phase 3 data holds up and regulators agree.

For Centessa, the deal is a validation of its focused R&D approach. The company, founded in 2021, has built its pipeline through an “asset-centric” model, advancing only the most promising candidates. The $6.3B price tag is a major premium over Centessa’s last public valuation.

What to Watch Next

This deal is part of a broader wave: Big Pharma is rediscovering neuroscience, lured by advances in brain science and a string of late-stage assets with first-in-class potential. Expect more M&A in sleep, neurodegeneration, and psychiatric disorders as pipelines mature and competition heats up.

For Lilly, the next big test is clinical. All eyes will be on Centessa’s Phase 3 readout—likely the gating factor for regulatory approval and commercial rollout. If the data hits, Lilly could have a new anchor in its neuroscience portfolio. If not, $6.3 billion is a steep price for a moonshot.